Membranous nephropathy: Mechanistic insights and therapeutic perspectives
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110317 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Meng-Ru Hua und 5 weiteren Autor:innen. Beteiligte Einrichtung: Xi'an International Medical Center Hospital, Northwest University, No. 777 Xitai Road, Xi'an, Shaanxi 710000, China. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Nephrotic Syndrome. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 150 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, National Key Research and Development Program of China Stem Cell and Translational Research.
Abstract (Originalsprache)
Membranous nephropathy (MN) is one of the most common causes of non-diabetic nephrotic syndrome in adults. About 80% of cases are renal limited (primary MN) and 20% are associated with other systemic diseases or exposures (secondary MN). Autoimmune reaction is the main pathogenic factor of MN, and the discovery of autoantigens including the phospholipase A2 receptor and thrombospondin type-1 domain-containing protein 7A has led to new insights into the pathogenesis, they can induce humoral immune responses led by IgG4 makes them suitable for the diagnosis and monitoring of MN. In addition, complement activation, genetic susceptibility genes and environmental pollution are also involved in MN immune response. In clinical practice, due to the spontaneous remission of MN, the combination of supportive therapy and pharmacological treatment is widely used. Immunosuppressive drugs are the cornerstone of MN treatment, and the dangers and benefits of this approach vary from person to person. In summary, this review provides a more comprehensive review of the immune pathogenesis, interventions and unresolved issues of MN in the hope of providing some new ideas for clinical and scientific researchers in the treatment of MN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xi'an International Medical Center Hospital, Northwest University, No. 777 Xitai Road, Xi'an, Shaanxi 710000, China.
- Guangdong nephrotic drug Engineering Technology Research Center, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, No. 71 Dongpeng avenue, Guangzhou, Guangdong 51053…
- School of Food and Bioengineering, Chengdu University, No. 2025 Chengluo Avenue, Chengdu, Sichuan 610106, China.
- Xi'an International Medical Center Hospital, Northwest University, No. 777 Xitai Road, Xi'an, Shaanxi 710000, China; School of Food and Bioengineering, Chengdu University, No. 2025 Chengluo Avenue, Chengdu, Sichuan 6101…
- Xi'an International Medical Center Hospital, Northwest University, No. 777 Xitai Road, Xi'an, Shaanxi 710000, China. Electronic address: lixia.1966@163.com.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- National Key Research and Development Program of China Stem Cell and Translational Research
- Shanxi Provincial Key Research and Development Project
Zitieren
APA
Hua, M. R., Zhao, Y. L., Yang, J. Z., Zou, L., Zhao, Y. Y., & Li, X. (2023). Membranous nephropathy: Mechanistic insights and therapeutic perspectives. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110317
Vancouver
Hua MR, Zhao YL, Yang JZ, Zou L, Zhao YY, Li X. Membranous nephropathy: Mechanistic insights and therapeutic perspectives. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110317
BibTeX
@article{Hua2023,
author = {Hua, Meng-Ru and Zhao, Yan-Long and Yang, Jun-Zheng and Zou, Liang and Zhao, Ying-Yong and Li, Xia},
title = {Membranous nephropathy: Mechanistic insights and therapeutic perspectives},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110317}
}
EUVIMED